Otsuka's Centanafadine Shows Promise for Executive Function and Emotional Regulation in Adult ADHD
Key Insights
New Phase 3 post hoc analyses demonstrate that centanafadine, a first-in-class NDSRI, improves executive function and emotional dysregulation in adults with ADHD (search) beyond core symptoms.
The study included 744 adults across two dose groups (200mg and 400mg) and showed statistically significant improvements in time management, planning, and emotional control at Week 6.
Centanafadine is currently under FDA Priority Review with a target action date of July 24, 2026, potentially addressing unmet needs in adult ADHD (search) treatment.
Otsuka Pharmaceutical (search) has unveiled promising new data for centanafadine, an investigational first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), showing the drug's potential to address executive function deficits and emotional dysregulation in adults with attention-deficit hyperactivity disorder (search) (ADHD (search)). The findings, presented at the 2026 American Society of Clinical Psychopharmacology Annual Meeting, represent post hoc analyses from two identical Phase 3 clinical trials and add to the growing evidence supporting centanafadine's comprehensive approach to ADHD treatment.
Addressing Underrecognized ADHD Features
The new analyses focused on two clinically meaningful but often underrecognized aspects of ADHD (search) that contribute substantially to patient burden: executive function deficits and emotional dysregulation. According to Dr. Lenard A. Adler, director of the adult ADHD program at NYU Langone Health and an investigator on the studies, "Executive function deficits and emotional dysregulation are challenging aspects of ADHD for many adults and are not always adequately addressed by current treatments."
The study included 744 adults divided across treatment groups: 242 patients receiving centanafadine 200 mg, 241 receiving centanafadine 400 mg, and 261 receiving placebo. At Week 6, patients treated with centanafadine demonstrated improved executive function compared with placebo, as measured by the Executive Functioning subscale of the Adult ADHD (search) Self-Report Scale (ASRS) Expanded Version.
Comprehensive Symptom Improvements
The executive function improvements encompassed multiple domains critical to daily functioning, including time management, planning and prioritization, task initiation and completion, and working memory. These findings reflect reductions in the frequency of patient-reported executive functioning difficulties, addressing areas that significantly impact quality of life for adults with ADHD (search).
Equally significant were the improvements observed in emotional dysregulation. Centanafadine was associated with reductions in emotional overactivity, affective lability, and anger outbursts, as measured by the ASRS Emotional Dyscontrol subscale at Week 6. These improvements represent progress in addressing what researchers consider areas of unmet need in ADHD (search) clinical care.
Clinical Trial Design and Safety Profile
The two pivotal Phase 3 trials (NCT03605680, NCT03605836) were randomized, double-blind, placebo-controlled studies evaluating centanafadine sustained-release tablets in adults aged 18 to 55 years with ADHD (search) over a 6-week treatment period. The primary endpoint was the change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at Week 6, with both centanafadine dose groups demonstrating statistically significant and clinically meaningful improvements versus placebo.
The drug maintained a favorable safety and tolerability profile with low potential for abuse and dependence. The most common adverse events included decreased appetite and headache, consistent with previous clinical data across pediatric, adolescent, and adult populations.
Regulatory Status and Clinical Significance
Centanafadine is currently under Priority Review by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of July 24, 2026. The Priority Review designation reflects the FDA's recognition of the drug's potential to address significant unmet medical needs in ADHD (search) treatment.
John Kraus, M.D., Ph.D., executive vice president and chief medical officer at Otsuka (search), emphasized the broader implications of these findings: "By showing improved symptoms in associated features, including executive function and emotional dysregulation, areas of unmet need in ADHD (search) clinical care, these data add to the understanding of centanafadine's clinical profile as a first-in-class NDSRI."
Market Context and Patient Impact
ADHD (search) affects approximately 7 million children and an estimated 15.5 million adults in the United States, according to the Centers for Disease Control and Prevention. The condition is characterized primarily by impairments in attention, hyperactivity, and impulsivity, but the new data highlight the importance of addressing the broader symptom profile that includes executive function and emotional regulation challenges.
The post hoc analyses complement Otsuka (search)'s previous research across age groups and provide new insights into centanafadine's potential to address ADHD (search) more holistically. As Dr. Adler noted, "Improvements across core ADHD symptoms and associated features, as the analyses show, are important considerations in the treatment of adults with ADHD, given the broad and variable symptom experience among patients and the need for approaches that address a range of manifestations of the condition."